Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.

For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• BAE Systems Plc (BA:LN) (BAESY) New Top Pick in EU Defence at Morgan Stanley
• Micron Technology (MU) PT Raised to $1,100 at Goldman Sachs